{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:49:32Z","timestamp":1760122172314,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.cjca.2012.05.003","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T14:31:21Z","timestamp":1345818681000},"page":"678-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Value of Drugs Targeting Inflammation for the Management of Coronary Artery Disease"],"prefix":"10.1016","volume":"28","author":[{"given":"Val\u00e9rie","family":"Duchatelle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterini A.","family":"Kritikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2012.05.003_bib1","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0002-8703(99)70266-8","article-title":"Atherosclerosis is an inflammatory disease","volume":"138","author":"Ross","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2012.05.003_bib2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.05.003_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.05.003_bib4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.05.003_bib6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.05.003_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5414\/CPP41567","article-title":"Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke","volume":"41","author":"Vrecer","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2012.05.003_bib8","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib10","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.05.003_bib11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.CIR.0000013424.28206.8F","article-title":"High-density lipoprotein restores endothelial function in hypercholesterolemic men","volume":"105","author":"Spieker","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib12","doi-asserted-by":"crossref","unstructured":"Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 200;107:2944-8.","DOI":"10.1161\/01.CIR.0000070934.69310.1A"},{"key":"10.1016\/j.cjca.2012.05.003_bib13","doi-asserted-by":"crossref","first-page":"19L","DOI":"10.1016\/S0002-9149(00)01464-8","article-title":"High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High\u2013Density Lipoprotein Intervention Trial","volume":"86","author":"Boden","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.05.003_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2006.04.006","article-title":"Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation","volume":"98","author":"Wolfram","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.05.003_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacl.2010.08.018","article-title":"Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?","volume":"4","author":"Tardif","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjca.2012.05.003_bib16","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1210\/jc.2010-0163","article-title":"Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease","volume":"96","author":"Brewer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cjca.2012.05.003_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with type 2 diabetes","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2012.05.003_bib19","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/ATVBAHA.110.222000","article-title":"Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages","volume":"31","author":"Tabet","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib20","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1084\/jem.184.5.1601","article-title":"Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia","volume":"184","author":"Pajkrt","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jacc.2008.12.008","article-title":"Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes","volume":"53","author":"Patel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.05.003_bib22","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1161\/01.CIR.0000127419.45975.26","article-title":"High-density lipoproteins neutralize C-reactive protein proinflammatory activity","volume":"109","author":"Wadham","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1655958","article-title":"Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia","volume":"77","author":"Pajkrt","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2012.05.003_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0037-1615194","article-title":"Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo","volume":"80","author":"Lerch","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2012.05.003_bib25","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.109.870709","article-title":"Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux","volume":"120","author":"Calkin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.ATV.19.2.378","article-title":"Inhibition of arterial thrombus formation by ApoA1 Milano","volume":"19","author":"Li","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.05.003_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.ATV.0000256728.60226.77","article-title":"The failure of torcetrapib: was it the molecule or the mechanism?","volume":"27","author":"Tall","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.05.003_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.05.003_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11883-008-0038-7","article-title":"Inflammatory signaling through leukotriene receptors in atherosclerosis","volume":"10","author":"Back","year":"2008","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2012.05.003_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa025079","article-title":"Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis","volume":"350","author":"Dwyer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1073\/pnas.242716099","article-title":"Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis","volume":"100","author":"Spanbroek","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2012.05.003_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp038190","article-title":"From asthma to atherosclerosis\u20135-lipoxygenase, leukotrienes, and inflammation","volume":"350","author":"De Caterina","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib35","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/01.ATV.0000172632.96987.2d","article-title":"Association between 5-lipoxygenase expression and plaque instability in humans","volume":"25","author":"Cipollone","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1183\/09031936.98.11030617","article-title":"Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients","volume":"11","author":"Lehnigk","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2012.05.003_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCIMAGING.110.937169","article-title":"Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome","volume":"3","author":"Tardif","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2012.05.003_bib38","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jacc.2009.02.068","article-title":"Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome","volume":"54","author":"Motoyama","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.05.003_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2007.03.044","article-title":"Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes","volume":"50","author":"Motoyama","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.05.003_bib42","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2741\/1862","article-title":"Serpins, the vasculature, and viral therapeutics","volume":"11","author":"Richardson","year":"2006","journal-title":"Front Biosci"},{"key":"10.1016\/j.cjca.2012.05.003_bib43","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.100.15.1616","article-title":"Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis","volume":"100","author":"Strauss","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/978-1-4419-1601-3_11","article-title":"The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics","volume":"666","author":"Lucas","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib45","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/01.CIR.94.11.2890","article-title":"Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty","volume":"94","author":"Lucas","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/CIRCINTERVENTIONS.110.953885","article-title":"A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention","volume":"3","author":"Tardif","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2012.05.003_bib47","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2012.05.003_bib48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cjca.2012.05.003_bib49","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1161\/CIRCULATIONAHA.108.771048","article-title":"P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice","volume":"117","author":"An","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib50","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1161\/01.CIR.0000065604.56839.18","article-title":"Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice","volume":"107","author":"Phillips","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/1566524043360609","article-title":"Trafficking of natural killer cells","volume":"4","author":"Morris","year":"2004","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.cjca.2012.05.003_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri1351","article-title":"Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation","volume":"4","author":"Ley","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cjca.2012.05.003_bib53","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.ATV.0000141844.28073.df","article-title":"Alpha(1,3)fucosyltransferases FucT-IV and FucT-VII control susceptibility to atherosclerosis in apolipoprotein E-\/- mice","volume":"24","author":"Homeister","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/ATVBAHA.109.187716","article-title":"Core2 1-6-N-glucosaminyltransferase-I deficiency protects injured arteries from neointima formation in ApoE-deficient mice","volume":"29","author":"Wang","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib55","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1111\/j.1538-7836.2009.03587.x","article-title":"P-selectin antagonism reduces thrombus formation in humans","volume":"7","author":"Chelliah","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cjca.2012.05.003_bib56","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2012.05.003_bib57","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2353\/ajpath.2006.051054","article-title":"Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice","volume":"168","author":"Chamberlain","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cjca.2012.05.003_bib58","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib59","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.CIR.0000085567.18648.21","article-title":"Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury","volume":"108","author":"Isoda","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.05.003_bib60","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1 beta in coronary arteries of patients with ischemic heart disease","volume":"16","author":"Galea","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.05.003_bib61","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0735-1097(00)01014-7","article-title":"Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting","volume":"36","author":"Kastrati","year":"2000","journal-title":"J Am Coll Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12002644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12002644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:35:47Z","timestamp":1760106947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X12002644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0828282X12002644"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2012.05.003","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Value of Drugs Targeting Inflammation for the Management of Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2012.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}